Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NY › Bethpage › NPI 1013998426
Hospital

Wsnchs North, INC.

Wsnchs North, INC. was paid $10.04M by Medicaid between Jan 2018 and Dec 2024, across 144 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.

33Billing provider infoWSNCHS NORTH, INC.
BETHPAGE, NY 11714
33aNPI1013998426assigned 11/11/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.04M
24GClaims274,871
24DCodes billed144
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in New York

Rank by total paid#83 of 231
Median peer was paid$561K
This provider vs. median18×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$100K$200K$300K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20184,292$157K
201916,805$509K
202037,314$1.30M
202155,048$1.93M
202253,007$1.99M
202359,703$2.22M
2024incomplete48,702$1.94M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 14% 9,260 8,896 $1.43M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 13% 8,556 8,200 $1.30M
96361 Intravenous infusion, hydration; each additional hour 10% 4,792 4,459 $1.01M
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 8.4% 5,209 4,482 $844K
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 7.9% 5,348 5,079 $794K
70450 Computed tomography, head or brain; without contrast material 6.0% 2,808 2,719 $605K
74177 Computed tomography, abdomen and pelvis; with contrast material 5.6% 2,449 2,398 $560K
G0378 Hospital observation service, per hour 5.5% 1,926 1,878 $556K
99282 Emergency department visit for the evaluation and management, low to moderate severity 5.0% 3,195 3,097 $498K
80053 Comprehensive metabolic panel 3.0% 15,775 13,940 $299K
74176 Computed tomography, abdomen and pelvis; without contrast material 2.8% 1,201 1,179 $282K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour 1.8% 988 962 $186K
132 more codes
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour 1.4% 1,008 $140K
0202U Oncology (prostate), multianalyte, gene expression profiling 1.2% 3,405 $123K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 1.1% 1,526 $112K
99281 Emergency department visit for the evaluation and management, self-limited or minor 1.1% 721 $109K
71275 Computed tomographic angiography, chest, with contrast material <1% 372 $97K
36415 Collection of venous blood by venipuncture <1% 18,848 $95K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 172 $93K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 1,428 $62K
86850 <1% 2,126 $57K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 1,501 $51K
86900 <1% 2,128 $48K
86901 <1% 2,129 $48K
M0243 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring <1% 133 $43K
92507 Treatment of speech, language, voice, communication, and/or auditory processing disorder <1% 375 $43K
83880 <1% 1,668 $42K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 1,551 $33K
80048 Basic metabolic panel (calcium, ionized) <1% 2,030 $30K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 5,986 $28K
95806 <1% 334 $28K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 148 $27K
96367 <1% 668 $26K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 2,342 $24K
J3490 Unclassified drugs <1% 2,042 $22K
M0245 Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring <1% 87 $21K
81025 <1% 7,884 $20K
96375 Therapeutic injection; each additional sequential IV push <1% 6,783 $19K
85610 <1% 5,402 $18K
87631 <1% 381 $18K
J0248 Injection, remdesivir, 1 mg <1% 30 $16K
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r <1% 235 $16K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 245 $13K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 300 $13K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 331 $9K
M0222 Intravenous injection, bebtelovimab, includes injection and post administration monitoring <1% 48 $9K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 358 $8K
71046 Radiologic examination, chest; 2 views <1% 1,923 $8K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 6,207 $7K
80061 Lipid panel <1% 729 $7K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 5,409 $7K
84702 <1% 2,056 $7K
99213 Doctor's office visit, returning patient (routine) <1% 27 $5K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 13,593 $5K
71045 Radiologic examination, chest; single view <1% 3,989 $5K
87581 <1% 331 $5K
87486 <1% 330 $5K
85027 <1% 1,889 $4K
90715 <1% 194 $4K
88304 <1% 138 $4K
80050 General health panel <1% 163 $4K
12001 <1% 12 $4K
87088 <1% 5,614 $3K
76830 Ultrasound, transvaginal <1% 52 $3K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 635 $3K
96376 <1% 1,467 $3K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 81 $2K
J7030 Infusion, normal saline solution , 1000 cc <1% 8,718 $2K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 17 $2K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 632 $2K
73630 <1% 308 $2K
82947 <1% 2,482 $2K
80076 <1% 134 $1K
G0108 Diabetes outpatient self-management training services, individual, per 30 minutes <1% 14 $1K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 81 $1K
85730 <1% 4,717 $1K
81003 <1% 7,203 $1K
83735 <1% 8,922 $1K
87070 <1% 856 $1K
J0131 Injection, acetaminophen, not otherwise specified,10 mg <1% 1,420 $943.85
72125 Computed tomography, cervical spine; without contrast material <1% 85 $882.98
84484 <1% 5,749 $849.86
83036 Hemoglobin; glycosylated (A1C) <1% 323 $774.34
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 85 $639.80
87186 <1% 547 $630.35
87077 <1% 558 $577.50
83690 <1% 4,803 $524.92
84100 <1% 6,730 $351.39
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 1,993 $347.82
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 3,985 $343.43
87040 <1% 2,487 $330.81
82550 <1% 2,376 $294.08
84443 Thyroid stimulating hormone (TSH) <1% 1,077 $293.94
83605 <1% 2,306 $285.63
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 14 $242.48
J0690 Injection, cefazolin sodium, 500 mg <1% 364 $186.20
Q9963 High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml <1% 12 $172.80
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 610 $145.06
82077 <1% 825 $134.85
85379 <1% 971 $111.51
J2704 Injection, propofol, 10 mg <1% 1,372 $107.57
J1170 Injection, hydromorphone, up to 4 mg <1% 799 $94.67
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 6,144 $83.20
80143 <1% 146 $80.43
S0028 Injection, famotidine, 20 mg <1% 1,538 $80.27
J0137 Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg <1% 366 $75.80
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 655 $59.87
80179 <1% 132 $58.16
J0136 Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg <1% 776 $54.62
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 55 $52.32
J2270 Injection, morphine sulfate, up to 10 mg <1% 1,471 $51.87
73030 <1% 52 $51.65
J3010 Injection, fentanyl citrate, 0.1 mg <1% 920 $50.35
74019 <1% 14 $48.59
J7050 Infusion, normal saline solution, 250 cc <1% 938 $47.11
Q9966 Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml <1% 68 $46.20
73562 <1% 88 $40.77
73610 <1% 60 $37.84
J7120 Ringers lactate infusion, up to 1000 cc <1% 63 $31.36
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 1,778 $29.40
85007 <1% 134 $29.09
84439 <1% 44 $25.48
84145 <1% 204 $23.39
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 876 $22.86
J2800 Injection, methocarbamol, up to 10 ml <1% 454 $18.10
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 1,406 $16.51
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 127 $13.56
73130 <1% 96 $12.63
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg <1% 100 $11.40
J3475 Injection, magnesium sulfate, per 500 mg <1% 752 $8.76
S0020 Injection, bupivicaine hydrochloride, 30 ml <1% 85 $3.52
J2060 Injection, lorazepam, 2 mg <1% 242 $3.33
J2003 Injection, lidocaine hydrochloride, 1 mg <1% 21 $1.20
J1171 Injection, hydromorphone, 0.1 mg <1% 45 $0.90
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 0% 13 $0.00
J3360 Injection, diazepam, up to 5 mg 0% 33 $0.00
84436 0% 139 $0.00
87276 0% 29 $0.00
86141 0% 15 $0.00
87275 0% 29 $0.00
J2919 Injection, methylprednisolone sodium succinate, 5 mg 0% 14 $0.00
99080 0% 75 $0.00
S0119 Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) 0% 13 $0.00
73110 0% 15 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialPALLAS, DREW (CHIEF FINANCIAL OFFICER/CHIEF OPERA)